Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder

NCT01699490 Phase 4 UNKNOWN

The purpose of this study is to identify evidence-based guidelines for treating major depressive disorder to full remission in Taiwanese major depressive disorder (MDD) patients. To achieve this goal, the investigators aim to: (1) evaluate the risks and benefits of adjunctive pharmacotherapies for cognitive and metabolic consequences in MDD, and (2) clarify the shared biological mechanisms between mood, immune and metabolism homeostasis

Details

Lead sponsor	National Cheng-Kung University Hospital
Phase	Phase 4
Status	UNKNOWN
Enrolment	200
Start date	2012-08
Completion	2015-07

Conditions

• Major Depressive Disorder

Interventions

• Fluoxetine + Valsartan
• Fluoxetine + Placebo

Primary outcomes

• Hamilton Depression Rating Scale (HDRS) — 12 weeks

Countries

Taiwan